Drug-induced systemic lupus erythematosus: Teports to the Netherlands Pharmacovigilance Centre Lareb;Geneesmiddelgeïnduceerde lupus erythematodes disseminatus: Meldingen aan Nederlands Bijwerkingen Centrum Lareb

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 6, 2007, Pages 367-370

  De Langen Wouterse, J J ^a   Bijl, A M H ^a   Van Grootheest, A C ^a  

^a Nederlands Bijwerkingen Centrum Lareb   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANTIBIOTIC AGENT; CAPTOPRIL; CHLORPROMAZINE; COTRIMOXAZOLE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; PENICILLAMINE; PROPYLTHIOURACIL; SALAZOSULFAPYRIDINE; TERBINAFINE;

ARTICLE; DRUG HYPERSENSITIVITY; DRUG USE; HUMAN; NETHERLANDS; SEX RATIO; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; DISEASE NOTIFICATION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NAPHTHALENES;

EID: 33847066264     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Putte LBA van de, Breedveld FC. Reumatische ziekten. In: Meer J van der, Stehouwer CDA, redacteuren. Interne geneeskunde. 12e dr. Houten: Bohn Stafleu van Loghum; 2001.
2. Hahn BH. Systemic lupus erythematosus. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine, 16th ed. New York: McGraw-Hill; 2005.
3. Sàrzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity. 2005;38:507-18.
4. Porter D, Harrison A. Minocycline-induced lupus: a case series. N Z Med J. 2003;116:0384.
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. 1981;30:239-45.
6. Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol. 1999;11:357-63.
7. Henn MJ, Parkin TW, Margraves MM, Odel HM. Acute systemic lupus erythematosus syndrome from hydralazine hydrochloride. AMA Arch Intern Med. 1955;95:857-62.
8. Reinhardt DJ, Waldron JM. Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy. J Am Med Assoc. 1954;155:1491-2.
9. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-80.
10. Hommes DW, Deventer SJH van. Infliximab therapy in Crohn's disease: safety issues. Neth J Med. 2003;61:100-4.
11. Farhi D, Viguier M, Cosnes A, Reygagne P, Dubertret L, Revuz J, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006;212:59-65.
12. McKay DA, Schofield OM, Benton EC. Terbinafine-induced subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2004;84:472-4.
13. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000;356:1587-91.
14. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosuslike syndrome. BMJ. 1996;312:169-72.